Loading
A phase 1/2 trial of Adebrelimab, SHR-8068, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC is a phase 1/2 interventional study registered as NCT06754930 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 400 participants planned, started 2025-02-18 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-1826, SHR-1316, SHR-9839, SHR-8068, Ametinib mesylate. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/